|
12 Feb 2019 |
Phase 3 ARCHES Trial Shows XTANDI® (enzalutamide) Significantly Improved Radiographic Progression-Free Survival in Men with Metastatic Hormone-Sensitive Prostate Cancer
|
|
12 Feb 2019 |
Gilead Announces Topline Data From Phase 3 STELLAR-4 Study of Selonsertib in Compensated Cirrhosis (F4) Due to Nonalcoholic Steatohepatitis (NASH)
|
|
12 Feb 2019 |
Aduro Announces First Patient Dosed in Phase 1 Study of ADU-S100 (MIW815) in Combination with YERVOY (ipilimumab) for the Treatment of Relapsed and Refractory Melanoma
|
|
12 Feb 2019 |
European Commission Approves Bristol-Myers Squibb’s Sprycel (dasatinib) in Combination with Chemotherapy for Treatment of Pediatric Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
|
|
09 Feb 2019 |
NuvOx Pharma’s NVX-208 Shows Positive Results in Phase Ib/II Stroke Trial
|
|
07 Feb 2019 |
Results on Efficacy of PMZ-1620, an Endothelin-B Agonist, from Ongoing Phase II Trial in Patients with Cerebral Ischemic Stroke Presented at International Stroke Conference 2019
|
|
06 Feb 2019 |
FDA Grants Priority Review for Daiichi Sankyo’s New Drug Application for CSF1R Inhibitor Pexidartinib for Treatment of Patients with TGCT, a Rare, Debilitating Tumor
|
|
05 Feb 2019 |
Idorsia announces the first patient recruited into REACT - the Phase 3 registration study with clazosentan
|
|
05 Feb 2019 |
FDA Accepts for Review New Drug Application (NDA) for Merck’s Investigational Combination of Imipenem/Cilastatin and Relebactam, and Supplemental NDA (sNDA) for ZERBAXA® (Ceftolozane and Tazobactam)
|
|
04 Feb 2019 |
Verseon Reports First Dosing in Phase 1 Trial on New Precision Oral Anticoagulant
|
|
04 Feb 2019 |
SK life science announces FDA acceptance of NDA submission for cenobamate, an investigational antiepileptic drug
|
|
04 Feb 2019 |
Neurana Pharmaceuticals Announces First Patient Enrolled in the "STAR Study," a Phase 2 Dose Ranging Study of Tolperisone in Acute Muscle Spasms of the Back
|
|
04 Feb 2019 |
Lilly Announces Top-Line Phase 3 Results for Baricitinib in Patients with Moderate to Severe Atopic Dermatitis
|
|
04 Feb 2019 |
Alkermes Receives Complete Response Letter From U.S. Food and Drug Administration for ALKS 5461 New Drug Application
|
|
04 Feb 2019 |
Eisai and Purdue Pharma Present Efficacy and Safety Data from Second Pivotal Phase 3 Study at the Sleep Research Society’s Conference: Advances in Sleep and Circadian Science
|
|
02 Feb 2019 |
Pfizer Receives Positive CHMP Opinion for Vizimpro® (dacomitinib) for the First-line Treatment of Adult Patients with Locally Advanced Or Metastatic Non-Small Cell Lung Cancer with EGFR-Activating Mutations
|
|
01 Feb 2019 |
Achillion Announces First Dosing in Phase 1 Multiple Ascending Dose Study of ACH-5228 Next-Generation Oral Factor D Inhibitor in Healthy Volunteers
|
|
01 Feb 2019 |
FDA Expands Lilly's ALIMTA® (pemetrexed) Label with Combination of KEYTRUDA® (pembrolizumab) and Platinum Chemotherapy for the First-Line Treatment of Metastatic Nonsquamous Non-Small Cell Lung Cancer
|
|
01 Feb 2019 |
Hua Medicine Initiates First Combination Study of Dorzagliatin with a DPP-4 Inhibitor in the United States
|
|
01 Feb 2019 |
OPKO Provides Update on the Development of OPK-88004, a Selective Androgen Receptor Modulator
|
|
31 Jan 2019 |
Cullinan Oncology to Develop Novel EBNA1 Inhibitor Discovered by The Wistar Institute
|
|
31 Jan 2019 |
Deinove is preparing initiation of Phase II for DNV3837 in Clostridium difficile infections, with a key partner
|
|
31 Jan 2019 |
Sanofi: Fexinidazole, the first all-oral treatment for sleeping sickness, approved in Democratic Republic of Congo
|
|
30 Jan 2019 |
Janssen Announces ERLEADA® (apalutamide) Phase 3 TITAN Study Unblinded as Dual Primary Endpoints Achieved in Clinical Program Evaluating Treatment of Patients with Metastatic Castration-Sensitive Prostate Cancer
|
|
30 Jan 2019 |
Axsome Therapeutics Initiates Phase 2 Trial of AXS-12 in Narcolepsy
|
